Couverture de Imaging in Precision Oncology

Imaging in Precision Oncology

Imaging in Precision Oncology

De : Fortrea
Écouter gratuitement

3 mois pour 0,99 €/mois

Après 3 mois, 9.95 €/mois. Offre soumise à conditions.

À propos de ce contenu audio

 Exploring the evolving role of imaging in precision oncology. We discuss the latest advancements in molecular imaging and how imaging is transforming patient selection, early response identification, and the design of clinical studies. Hygiène et vie saine Maladie et pathologies physiques Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Ep 1 | Redefining Precision Oncology: Imaging Innovations Driving Clinical Trials

      Ep 1 | Redefining Precision Oncology: Imaging Innovations Driving Clinical Trials
      Jan 23 2026
      In this episode, host Laura Vidal, VP of Oncology at Fortrea, sits down with Dr. Ron Korn, Founder and Chief Medical Officer of Imaging Endpoints, to explore the evolving role of imaging in precision oncology. The conversation covers the latest advancements in molecular imaging, including PSMA PET for prostate cancer and the integration of AI-driven radiomics in clinical trials. The episode highlights how imaging is transforming patient selection, early response identification, and the design of clinical studies. Listeners will gain an understanding of the challenges and opportunities in aligning imaging with liquid biopsy data, the rise of theranostics, and the regulatory landscape shaping the future of drug development. With practical examples and visionary perspectives, this attachment offers a comprehensive look at how imaging endpoints are driving innovation in oncology and beyond. If you’re involved in clinical research or interested in the future of medical imaging, this episode—is a must-listen.
      Afficher plus Afficher moins
      18 min
    Aucun commentaire pour le moment